Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (industry) · PFE — their whole pipeline →. With Genmab, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgian Gynaecological Oncology Group, GOG Foundation and 1 more.

Phase

Phase 1/2

Status

Terminated

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

214actual

Sites

Countries

Belgium, Czechia, Denmark +7

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

Sponsor has decided to stop the trial based on strategic decisions

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2019-02-27

actual

When the study began enrolling

Primary completion

2026-03-19

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-03-19

actual

The whole study's end, after follow-up

First posted

2018-12-24

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-22

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Cervical Cancer

Interventions

Drug: Tisotumab Vedotin — also filed as TIVDAK
Drug: Bevacizumab — also filed as Avastin
Drug: Pembrolizumab — also filed as KEYTRUDA®
Drug: Carboplatin — also filed as Paraplatin

Primary outcomes

what the primary-completion date above is the date OF

Dose escalation: Dose Limiting Toxicities (DLTs)

measured DLTs will be identified during the first treatment cycle (21 day cycles)

Dose expansion: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

measured approximately 2 years

Publications

PMID 42000372 — linked by the registry
PMID 37651655 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed